Treatment Algorithms in Melanoma: Past, Present, and Future

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Pembrolizumab vs Ipilimumab: OS Results

Combination Therapy: 3-Year OS

Combination Therapy vs Monotherapy With a PD-1 Inhibitor

IDO

IDO Inhibition: Epacadostat

Potential Mechanisms of Combination Approaches With IDO Inhibitors

IDO Inhibition: Epacadostat

IDO Inhibition: Indoximod

LAG-3

LAG-3 Inhibition

T-Vec + Ipilimumab

T-Vec + Pembrolizumab

Costimulatory Molecules

When Is It Safe to Stop Therapy?

Data on Stopping Therapy From NSCLC

Treatment Beyond Progression

Sequencing

Long-Term Survival Data for Targeted Therapy

Brain Metastases

Combining Targeted Therapy With Checkpoint Inhibition

Adjuvant Immunotherapy

Adjuvant Therapy With Nivolumab

Treat Early or Later?

Adjuvant Therapy With Targeted Therapies

Treating Patients With Stage III Melanoma

Concluding Remarks